BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025
• 2026

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October
• November
• December

Day

• 2
• 3
• 4
• 5
• 6
• 7
• 10
• 11
• 12
• 13
• 14
• 17
• 18
• 19
• 20
• 21
• 24
• 25
• 26
• 27
• 28
• 31

• Press Releases

  Primary Endpoint Met in Corcept’s Pivotal Phase 3 ROSELLA Trial of Relacorilant in Patients with Platinum-Resistant Ovarian Cancer

  March 31, 2025

   · 

  6 min read
• 

  Approvals

  Sanofi, Alnylam Win First RNAi Approval for Hemophilia A and B

  Unlike other hemophilia therapies, Qfitlia is indicated for both hemophilia A and B, and can be given in patients regardless of the presence of neutralizing antibodies against clotting factor VIII or IX.

  March 31, 2025

   · 

  2 min read

   · 

  Tristan Manalac
• Press Releases

  Adagio Medical Reports Fourth Quarter and Full Year 2024 Results

  March 31, 2025

   · 

  6 min read
• 

  Cardiovascular disease

  Lilly’s RNA Silencer Lowers Key Cardiovascular Biomarker by Almost 94%

  BMO Capital Markets analysts said the results potentially position lepodisiran as “one of the most durable assets in development to date” in the competitive Lp(a) space, where drugs are designed to lower the risk of cardiovascular events such as heart attack and stroke.

  March 31, 2025

   · 

  2 min read

   · 

  Tristan Manalac
• Press Releases

  Forte Biosciences, Inc. Announces Results and Provides Clinical Update

  March 31, 2025

   · 

  7 min read
• Press Releases

  Quantum BioPharma Provides Corporate Update

  March 31, 2025

   · 

  4 min read
• Press Releases

  NervGen Initiates Expanded Access Policy

  March 31, 2025

   · 

  8 min read
• Press Releases

  BioMark Announces the Final Closing of Oversubscribed Private Placement

  March 31, 2025

   · 

  8 min read
• 

  FDA

  Marks’ Sudden Departure From FDA Magnifies Uncertainty, Sends Biopharma Shares Down

  The stock market—and biotech insiders—reacted negatively to the allegedly forced resignation of CBER Director Peter Marks, who said RFK Jr. does not seek “truth and transparency” but rather “subservient confirmation of his misinformation and lies.”

  March 31, 2025

   · 

  3 min read

   · 

  Heather McKenzie
• Press Releases

  Corporate Update: Psyence Biomedical Ltd Redefines Psychedelic Medicine with a Multi-Asset Strategy, Advancing Clinical Trials and Scalable Manufacturing

  Company executives will host a corporate webinar for investors and stakeholders on Thursday, April 10, 2025

  March 31, 2025

   · 

  12 min read